Souhaitez-vous accéder aux communiqués récents ?

FDA has approved Awiqli® injection 700 units/mL, the first and only once-weekly, long-acting basal insulin as an adjunct to diet and exercise to improve ..

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between...

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer...

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

RA'ANANA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic...

Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and...

Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under...

SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy...

GARDEN CITY, N.Y., March 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on...

- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum -- Life Sciences: R2 Secures 600‑System Commitment in China -- Spectrum: Recent network launches set to...

Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25Welcomed second favorable head-to-head data set from an independent study at large hospital...

Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025In February, Spero’s...

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil’s National Health...

On track for DENALI Part 2a dose confirmation in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalOn track to initiate the ASPENOVA Phase...

Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment...

WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to...

WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to...

Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30...

Ghent, Belgium, March 26, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASE REGULATED INFORMATION - INSIDE INFORMATION26 March 2026, 8:00 pm CET Ghent, Belgium, 26 March 2026 – Sequana Medical NV (Euronext...

LOS ANGELES, March 26, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming April 21, 2026 deadline to file a lead plaintiff motion in the class action...

New class action for uniQure N.V. (QURE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/13/2026.

New class action for Inovio (INO) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/7/2026.

New class action for Atara (ATRA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/22/2026.

Outgrow the chemical era. HairSmart leads 2026’s "Clean Bio-Hacking" trend, fusing FDA-cleared LLLT with Ayurveda for side-effect-free hair restoration.

Fairfield, Connecticut, March 26, 2026 (GLOBE NEWSWIRE) -- Bigelow Tea, America's number one family and woman-owned tea company, sources only premium ingredients from the United States and from...

Raanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective...

March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures, supporting treatment [2]DeviceGuide integrates...

-- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage...

ROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided...

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) lost approximately 70% of their holdings after the FDA issued a Complete Response Letter for...

NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- NEW YORK, March 26, 2026 -- Grail, Inc. (NASDAQ: GRAL) lost approximately 50% of its market value after disclosing that the NHS Galleri randomized trial...

LOS ANGELES, March 26, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aquestive Therapeutics, Inc., (“Aquestive” or the "Company") (NASDAQ: AQST) investors off a class action on behalf of...

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare

TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath® as a Stand-Alone Device for...

Austin, United States, March 26, 2026 (GLOBE NEWSWIRE) -- Red Biotechnology Market Size & Growth Analysis: The global Red Biotechnology Market is in its transformational growth phase. According...

– Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe  – Advances Proposed Expedited...

SEATTLE and VANCOUVER, British Columbia, March 26, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global...

Emory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System

The Soleno complaint alleges that Soleno Phase 3 clinical trial program for DCCR had downplayed, misrepresented, and/or concealed safety concerns.

FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tractMeiraGTx to hold...

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a...

OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the...

- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. -  - He will work with the Company’s leadership team to expand...

FOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer,...

Virtual Event will feature Key Opinion Leaders (KOLs) Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR Cue Biopharma management and KOLs will discuss CUE-401, the company’s lead asset for the...

Milestone announcement at SAGES 2026 underscores accelerating adoption of Versius as CMR prepares for U.S. expansion following recent FDA clearance CAMBRIDGE, UK and TAMPA, FL – March 26, 2026 — CMR...

Firefly’s AI-powered, FDA-cleared EEG/ERP Technology is Being Deployed to Support Assessment and Treatment of PTSD and TBI in U.S. Service Members Partnership Represents a Significant Expansion of...

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic...

-Advancing zervimesine clinical development in DLB psychosis – - Meeting with FDA Division of Psychiatry expected by mid-2026 -- Management conference call at 8:30 a.m. ET today - PURCHASE, N.Y.,...